TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10475150

Group type: EXPERIMENTAL
Intervention: Octreotide (50 microg subcutaneous injections at 18:00 h and 23:00 h)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (subcutaneous injections at 18:00 h and 23:00 h)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Octreotide (50 microg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study: 8611872

Group type: EXPERIMENTAL
Intervention: Immediate postoperative enteral feeding through a nasojejunal tube
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional postoperative intravenous fluids
Number of subjects: 30
Study: 1931399

Group type: EXPERIMENTAL
Intervention: Morphine 10 mg i.m.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ketorolac 30 mg i.m.
Number of subjects: 10
Study: 6214264

Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 8 g cholestyramine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4 g cholestyramine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All doses of cholestyramine
Number of subjects: 19
Study: 31743169

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg (D 1)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg (D 0.5)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 µg/kg (D 0.25)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (all doses)
Number of subjects: 190
Study: 30253746

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (CG) - cycling
Number of subjects: 20
Study: 27852708

Group type: EXPERIMENTAL
Intervention: Aveeno lotion
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Diprobase cream
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Doublebase gel
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Hydromol ointment
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Other non-study emollients
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Daily diaries
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Observer blinding
Number of subjects: 197
Study: 24492633

Group type: EXPERIMENTAL
Intervention: SIT‐Q‐7d (Dutch version)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SIT‐Q‐7d (English version)
Number of subjects: 453
Study: 22162175

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 51

Group type: COMPARATOR
Intervention: Heparin plus abciximab
Number of subjects: 51
Study: 21058823

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial (RCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other methods of inquiry
Number of subjects: 0
Study: 17409317

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Overall treatment (Losartan and Placebo)
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Combined SBP and albuminuria reduction
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Lower residual level of albuminuria
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: Changes in albuminuria
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: SBP or albuminuria reduction
Number of subjects: 1428
Study: 16464424

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11806863

Group type: EXPERIMENTAL
Intervention: 40 mg of propranolol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9726683

Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg q.d. for 14 days)
Number of subjects: 3413

Group type: COMPARATOR
Intervention: No treatment (nasal saline drops allowed)
Number of subjects: 3413
Study: 8039152

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Sequential tamoxifen/megestrol for 2 years
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: High‐dose chemotherapy+autologous bone marrow transplantation
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Postoperative radiotherapy to the breast
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: CMF- or FEC-chemotherapy plus APD (pamidronate)
Number of subjects: 1600
Study: 2743845

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30793734

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg with P2Y12 inhibitor
Number of subjects: 2725

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg with P2Y12 inhibitor
Number of subjects: 2725

Group type: COMPARATOR
Intervention: Dabigatran dual therapy
Number of subjects: 2725
Study: 27655276

Group type: EXPERIMENTAL
Intervention: Buccal oxygenation via a modified 3.5‐mm Ring‐Adair‐Elwyn (RAE) tube
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 25744196

Group type: EXPERIMENTAL
Intervention: Low-flux hemodialysis (LF-HD)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HF-HD)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 31
Study: 23846588

Group type: EXPERIMENTAL
Intervention: Overcoming Addictions (OA) alone
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: OA+attend SMART Recovery (SR) meetings (OA+SR)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Attend SMART Recovery (SR) only
Number of subjects: 189
Study: 21327867

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (DIWL)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EX)
Number of subjects: 16
Study: 19959920

Group type: EXPERIMENTAL
Intervention: Individually tailored intervention program consisting of physical and daily activities led by physiotherapists and occupational therapists for three months
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study: 17303627

Group type: EXPERIMENTAL
Intervention: Catheter ablation with combined lesions in the right and left atria
Number of subjects: 126

Group type: COMPARATOR
Intervention: Best antiarrhythmic drug therapy
Number of subjects: 126
Study: 15536458

Group type: EXPERIMENTAL
Intervention: Citrus aurantium
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Milk thistle
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Saw palmetto
Number of subjects: 12
Study: 10678834

Group type: EXPERIMENTAL
Intervention: Repetition of familiar stimuli (faces and symbols)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition of unfamiliar stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition effects with varying lag between presentations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple repetitions of stimuli
Number of subjects: 0
Study: 9035428

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Petroleum jelly
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Lactitol and Petroleum jelly
Number of subjects: 110
Study: 1540109

Group type: EXPERIMENTAL
Intervention: Taste Aversion Group (CS1‐US‐CS2‐Test)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overshadowing Group (CS1‐CS2‐US‐Test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (US‐CS1‐CS2‐Test)
Number of subjects: 0
Study: 4039870

Group type: EXPERIMENTAL
Intervention: Acellular preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 0
Study: 31812284

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30946926

Group type: EXPERIMENTAL
Intervention: Countdown timer group (3000 ms constant foreperiod with a 1000 ms countdown timer)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Single key-press response
Number of subjects: 36

Group type: COMPARATOR
Intervention: Three key-presses with equal/isochronous time interval
Number of subjects: 36

Group type: COMPARATOR
Intervention: Three key-presses with unequal/non-isochronous time interval
Number of subjects: 36
Study: 29454724

Group type: EXPERIMENTAL
Intervention: Silent diabetes detected by OGTT
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Pre-diabetes detected by OGTT
Number of subjects: 988

Group type: COMPARATOR
Intervention: Normal glucose metabolism
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Silent diabetes detected by glycosylated hemoglobin and fasting plasma glucose
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Pre-diabetes detected by glycosylated hemoglobin and fasting plasma glucose
Number of subjects: 988

Group type: COMPARATOR
Intervention: Normal glucose metabolism (glycosylated hemoglobin and fasting plasma glucose)
Number of subjects: 988

Group type: EXPERIMENTAL
Intervention: Abnormal glucose metabolism (both diagnostic approaches)
Number of subjects: 988
Study: 26926775

Group type: EXPERIMENTAL
Intervention: Rifaximin alone (550 mg twice daily for 3 months)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Rifaximin in combination with lactulose (30-60 ml daily for 3 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study: 24738713

Group type: EXPERIMENTAL
Intervention: CPAP 5 cm H2O + PSV 5 cm H2O (CPAP/PSV, n = 22)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Neutral-pressure breathing without CPAP/PSV (control, n = 22)
Number of subjects: 44
Study: 21887685

Group type: COMPARATOR
Intervention: No bortezomib (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m2 × 3 doses (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.5 mg/m2 × 3 doses (Group 3)
Number of subjects: 60
Study: 19091394

Group type: COMPARATOR
Intervention: Endocrine treatment alone (3 months of total androgen blockade followed by continuous endocrine treatment using flutamide)
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus radiotherapy
Number of subjects: 875

Group type: COMPARATOR
Intervention: Endocrine treatment alone
Number of subjects: 875
Study: 18158693

Group type: EXPERIMENTAL
Intervention: Instructions to land softer
Number of subjects: 25

Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 25
Study: 15149346

Group type: COMPARATOR
Intervention: High flux dialysis
Number of subjects: 1846

Group type: COMPARATOR
Intervention: High dose dialysis
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Standard dose dialysis
Number of subjects: 1846

Group type: EXPERIMENTAL
Intervention: All randomized groups
Number of subjects: 1846
Study: 12696398

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sulfadoxine/pyrimethamine (SP)
Number of subjects: 98
Study: 10690147

Group type: EXPERIMENTAL
Intervention: Portex Soft Seal tube cuff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mallinckrodt Lo‐Contour tube cuff
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portex Profile tube cuff
Number of subjects: 0
Study: 8917264

Group type: EXPERIMENTAL
Intervention: 17‐beta‐estradiol patches (100 micrograms/24 h)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2060286

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: halothane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: etomidate/fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: multiparametric methods
Number of subjects: 30

Group type: COMPARATOR
Intervention: single parametric methods
Number of subjects: 30
Study: 6837016

Group type: EXPERIMENTAL
Intervention: Internists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laboratory tests ordered by family practitioners
Number of subjects: 0
Study: 3885664

Group type: EXPERIMENTAL
Intervention: Single-dose (1 g) intravenous metronidazole prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis and doxycycline therapy in case of perforation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated controls for unperforated appendix
Number of subjects: 0
Study: 30695291

Group type: EXPERIMENTAL
Intervention: Aripiprazole augmentation
Number of subjects: 1522

Group type: EXPERIMENTAL
Intervention: Bupropion augmentation
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Switching to bupropion
Number of subjects: 1522
Study: 26816605

Group type: EXPERIMENTAL
Intervention: Subject-driven titration of BIAsp 30 BID
Number of subjects: 344

Group type: COMPARATOR
Intervention: Investigator-driven titration of BIAsp 30 BID
Number of subjects: 344
Study: 25337749

Group type: COMPARATOR
Intervention: Control regimen (2 months of ethambutol, isoniazid, rifampicin, and pyrazinamide followed by 4 months of daily isoniazid and rifampicin)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: 6-month regimen (daily moxifloxacin for 2 months followed by weekly moxifloxacin and 1200 mg rifapentine for 4 months)
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: 4-month regimen (daily moxifloxacin for 2 months followed by moxifloxacin and 900 mg rifapentine twice weekly for 2 months)
Number of subjects: 827
Study: 23538567

Group type: EXPERIMENTAL
Intervention: Low educational status (4 to 10 years) in PD group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High educational status (≥11 years) in PD group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low educational status (4 to 10 years) in control group
Number of subjects: 28

Group type: COMPARATOR
Intervention: High educational status (≥11 years) in control group
Number of subjects: 28
Study: 19935072

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surface anatomy guidance (group SA)
Number of subjects: 60
Study: 17426742

Group type: EXPERIMENTAL
Intervention: Muesli with 4 g beta-glucans
Number of subjects: 32

Group type: COMPARATOR
Intervention: Muesli with 3 g beta-glucans
Number of subjects: 32

Group type: COMPARATOR
Intervention: Reference meal without beta-glucans
Number of subjects: 32
Study: 17127465

Group type: EXPERIMENTAL
Intervention: Brown rice
Number of subjects: 19

Group type: COMPARATOR
Intervention: Milled rice
Number of subjects: 19
Study: 14607575

Group type: EXPERIMENTAL
Intervention: Oral sibutramine (10 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral EE‐CPA (35 microg‐2 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of EE‐CPA plus sibutramine
Number of subjects: 40
Study: 11004041

Group type: EXPERIMENTAL
Intervention: IHNB-MAC
Number of subjects: 81

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 81

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 81
Study: 8848411

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 28
Study: 1633069

Group type: EXPERIMENTAL
Intervention: Solid micellar solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Faster releasing microemulsion formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard soft gelatine preparation
Number of subjects: 12
Study: 6425910

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 30678657

Group type: EXPERIMENTAL
Intervention: Genetic variants associated with postoperative complications
Number of subjects: 1170

Group type: EXPERIMENTAL
Intervention: New-onset of atrial fibrillation, delirium, myocardial infarction, acute kidney injury and stroke
Number of subjects: 1170
Study: 29501739

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise intervention for six months
Number of subjects: 254

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study: 27185903

Group type: EXPERIMENTAL
Intervention: Active nicotine pressurized metered dose inhaler (pMDI) plus active nicotine patch
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo pMDI plus active nicotine patch
Number of subjects: 502
Study: 24630572

Group type: EXPERIMENTAL
Intervention: Follicular fluid group (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study: 22919348

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) with conventional medical treatment, 10 sessions within 3-5 days after stroke onset.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional medical treatment without HBOT.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of changes in NIHSS scores between HBOT and control groups.
Number of subjects: 46
Study: 20200258

Group type: EXPERIMENTAL
Intervention: 7 home-delivered therapeutic DASH meals per week for 12 months
Number of subjects: 298
Study: 17665483

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every other week for 24 weeks
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 16096124

Group type: EXPERIMENTAL
Intervention: Preferred treatment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Non-preferred treatment
Number of subjects: 122
Study: 12394705

Group type: EXPERIMENTAL
Intervention: Bilateral sacral neuromodulation
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unilateral sacral neuromodulation
Number of subjects: 33
Study: 9464714

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 0.625 mg daily (Group C)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and conjugated equine estrogens 1.25 mg daily (Group D)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + placebos for progestin and estrogen (Group A)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg daily and placebo for estrogen (Group B)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily (Group C)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg every 4 weeks + norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily (Group D)
Number of subjects: 201
Study: 7589597

Group type: EXPERIMENTAL
Intervention: Total body PET with FDG
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine imaging (CT pelvis, CT/US liver and CXR)
Number of subjects: 76
Study: 2773686

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen administered continuously via programmable pump (90 to 150 micrograms per day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intrathecal morphine single injection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Baclofen bolus injection (30 to 60 micrograms)
Number of subjects: 14
Study: 907460

Group type: EXPERIMENTAL
Intervention: Crystalloid resuscitation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colloid resuscitation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crystalloid and colloid resuscitation
Number of subjects: 20
Study: 31563866

Group type: EXPERIMENTAL
Intervention: Treat-and-extend ranibizumab (T&E)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Monthly ranibizumab
Number of subjects: 529
Study: 30572163

Group type: EXPERIMENTAL
Intervention: Collaborative Care intervention (12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention Control condition (12 weeks)
Number of subjects: 100
Study: 28127849

Group type: EXPERIMENTAL
Intervention: Group 1 (brief lecture and training exercise)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group 2 (only lecture)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group 3 (only training exercise)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Group 4 (control group, no intervention)
Number of subjects: 120
Study: 26735264

Group type: EXPERIMENTAL
Intervention: Oral α-lipoic acid (ALA), betamethasone injection, and NB-UVB
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, betamethasone injection, and NB-UVB
Number of subjects: 50
Study: 25046949

Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Recipe (YHR) combined with routine therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Routine therapy + placebo (Control)
Number of subjects: 43
Study: 23520670

Group type: EXPERIMENTAL
Intervention: Oral propranolol 20 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral propranolol 40 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no anxiolytic premedication)
Number of subjects: 60
Study: 19820226

Group type: EXPERIMENTAL
Intervention: New outcome measure instruments for vasculitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Core set of outcome measures for vasculitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing projects providing data on outcomes
Number of subjects: 0
Study: 18034677

Group type: EXPERIMENTAL
Intervention: Galvano-ceramic crowns
Number of subjects: 52

Group type: COMPARATOR
Intervention: Metal-ceramic crowns
Number of subjects: 52
Study: 15186875

Group type: EXPERIMENTAL
Intervention: 9-month educational diabetes programme tailored to Turkish patients, provided by Turkish bicultural female educators
Number of subjects: 54
Study: 11413842

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Number of subjects: 312

Group type: COMPARATOR
Intervention: Paracetamol (PAR) 1 g twice daily on Day 1 and 1 g three times daily on Day 2
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LAS)
Number of subjects: 312
Study: 9065296

Group type: EXPERIMENTAL
Intervention: Hepatic cryosurgery (group 1, n = 63)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Conventional surgical techniques (group 2, n = 60)
Number of subjects: 123